UCB SA PT receives Investment Bank Analyst Rating Update
Investing.com - UCB reported on Thursday second quarter earnings that missed analysts' forecasts and revenue that was inline with expectations. UCB announced earnings per share...
Investing.com - UCB reported on Thursday fourth quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. UCB announced earnings per share of...
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.